Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-18 |
ADCOCK INGRAM Jun-14 |
SANOFI INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 6,840 | 383 | - | |
Low | Rs | 4,630 | 276 | - | |
Sales per share (Unadj.) | Rs | 1,203.1 | 113.9 | - | |
Earnings per share (Unadj.) | Rs | 165.3 | -28.7 | - | |
Cash flow per share (Unadj.) | Rs | 209.9 | -23.8 | - | |
Dividends per share (Unadj.) | Rs | 84.00 | 0 | - | |
Dividend yield (eoy) | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 963.6 | 89.4 | - | |
Shares outstanding (eoy) | m | 23.03 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.8 | 2.9 | 164.7% | |
Avg P/E ratio | x | 34.7 | -11.5 | -302.2% | |
P/CF ratio (eoy) | x | 27.3 | -13.9 | -197.2% | |
Price / Book Value ratio | x | 6.0 | 3.7 | 161.5% | |
Dividend payout | % | 50.8 | 0 | - | |
Avg Mkt Cap | Rs m | 132,078 | 55,608 | 237.5% | |
No. of employees | `000 | 3.3 | 4.3 | 76.9% | |
Total wages/salary | Rs m | 4,068 | 3,490 | 116.6% | |
Avg. sales/employee | Rs Th | 8,393.8 | 4,476.9 | 187.5% | |
Avg. wages/employee | Rs Th | 1,232.4 | 813.0 | 151.6% | |
Avg. net profit/employee | Rs Th | 1,153.0 | -1,128.1 | -102.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,708 | 19,219 | 144.2% | |
Other income | Rs m | 897 | 135 | 666.5% | |
Total revenues | Rs m | 28,605 | 19,354 | 147.8% | |
Gross profit | Rs m | 6,235 | -3,331 | -187.2% | |
Depreciation | Rs m | 1,027 | 829 | 123.8% | |
Interest | Rs m | 7 | 521 | 1.3% | |
Profit before tax | Rs m | 6,098 | -4,546 | -134.1% | |
Minority Interest | Rs m | 0 | -13 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,292 | 284 | 806.9% | |
Profit after tax | Rs m | 3,806 | -4,843 | -78.6% | |
Gross profit margin | % | 22.5 | -17.3 | -129.9% | |
Effective tax rate | % | 37.6 | -6.2 | -601.5% | |
Net profit margin | % | 13.7 | -25.2 | -54.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,922 | 14,076 | 113.1% | |
Current liabilities | Rs m | 6,235 | 7,920 | 78.7% | |
Net working cap to sales | % | 35.0 | 32.0 | 109.1% | |
Current ratio | x | 2.6 | 1.8 | 143.7% | |
Inventory Days | Days | 64 | 111 | 57.4% | |
Debtors Days | Days | 21 | 124 | 16.8% | |
Net fixed assets | Rs m | 7,539 | 8,205 | 91.9% | |
Share capital | Rs m | 230 | 89 | 257.8% | |
Net worth | Rs m | 22,192 | 15,085 | 147.1% | |
Long term debt | Rs m | 0 | 5,301 | 0.0% | |
Total assets | Rs m | 29,839 | 28,497 | 104.7% | |
Interest coverage | x | 872.1 | -7.7 | -11,279.3% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.7 | 137.7% | |
Return on assets | % | 12.8 | -15.2 | -84.3% | |
Return on equity | % | 17.2 | -32.1 | -53.4% | |
Return on capital | % | 27.5 | -19.8 | -138.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,739 | 1,640 | 227.9% | |
From Investments | Rs m | -731 | -504 | 145.1% | |
From Financial Activity | Rs m | -1,972 | 4,811 | -41.0% | |
Net Cashflow | Rs m | 1,036 | 5,948 | 17.4% |
Compare SANOFI INDIA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SANOFI INDIA With: DR. DATSONS LABS SUVEN LIFE SCIENCES ORCHID PHARMA VENUS REMEDIES AUROBINDO PHARMA
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More